Literature DB >> 328207

Pharmacokinetics and response to diazoxide in renal failure.

R M Pearson.   

Abstract

Diazoxide is given by rapid intravenous injection for the urgent reduction of high blood pressure in patients with all grades of renal function. Oral diazoxide produces less consistent effects. Protein binding of diazoxide is reduced in renal failure and this can be related to reduction of albumin concentration. There is a relation between impairment of renal function and the hypotensive effect of rapidly injected diazoxide. This is explicable in terms of the greater concentration of free (unbound) drug achieved after rapid injection in patients with renal failure. Renal clearance of diazoxide and its metabolites is impaired in renal failure but this is unlikely to affect its activity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 328207     DOI: 10.2165/00003088-197702030-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  27 in total

1.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

2.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

3.  Disposition of diazoxide in children.

Authors:  A W Pruitt; P G Dayton; J H Patterson
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

4.  Protein binding and vascular activity of diazoxide.

Authors:  E M Sellers; J Koch-Weser
Journal:  N Engl J Med       Date:  1969-11-20       Impact factor: 91.245

5.  A comparison of the binding of drugs to adult and cord plasma.

Authors:  A W Pruitt; P G Dayton
Journal:  Eur J Clin Pharmacol       Date:  1971-12       Impact factor: 2.953

6.  Nonketoacidotic hyperglycemia and coma during intravenous diazoxide therapy in uremia.

Authors:  M A Charles; E Danforth
Journal:  Diabetes       Date:  1971-07       Impact factor: 9.461

7.  Metabolism of diazoxide in man and experimental animals.

Authors:  A W Pruitt; B A Faraj; P G Dayton
Journal:  J Pharmacol Exp Ther       Date:  1974-01       Impact factor: 4.030

8.  Importance of dissolution rates in producing effective diazoxide blood levels in man.

Authors:  B Calesnick; B Katchen; J Black
Journal:  J Pharm Sci       Date:  1965-09       Impact factor: 3.534

9.  The use of diazoxide in hypertensive crises with particular reference to the control of hypertension in severe renal failure.

Authors:  T H Mathew; P Kincaid-Smith
Journal:  Drugs       Date:  1971       Impact factor: 9.546

10.  Renal function, protein binding and pharmacological response to diazoxide.

Authors:  R M Pearson; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1976-02       Impact factor: 4.335

View more
  6 in total

1.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 3.  Interrelationship between renal haemodynamics, drug kinetics and drug action.

Authors:  K L Duchin; R W Schrier
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 4.  The pharmacological role of the kidney.

Authors:  D C Brater
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

6.  Free Drug Theory - No Longer Just a Hypothesis?

Authors:  Scott G Summerfield; James W T Yates; David A Fairman
Journal:  Pharm Res       Date:  2022-02-02       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.